AZD-1940

AZD-1940
Clinical data
Other namesAZD1940; ART27.13; ART-27.13; ART-2713; ART2713; NEO-1940; NEO1940
Routes of
administration
Oral
Legal status
Legal status
Identifiers
  • N-{1-[(4,4-difluorocyclohexyl)methyl]-2-(1,1-dimethylethyl)-1H-benzimidazol-5-yl}ethanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H29F2N3O2S
Molar mass413.53 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)Nc1ccc2c(c1)nc(n2CC3CCC(CC3)(F)F)C(C)(C)C
  • InChI=1S/C20H29F2N3O2S/c1-5-28(26,27)24-15-6-7-17-16(12-15)23-18(19(2,3)4)25(17)13-14-8-10-20(21,22)11-9-14/h6-7,12,14,24H,5,8-11,13H2,1-4H3
  • Key:ZAGGGZCIFUQHOH-UHFFFAOYSA-N

AZD-1940, also known as ART27.13 or NEO-1940, is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the cannabinoid CB1 and CB2 receptors. It was developed for the treatment of neuropathic pain, but while it showed good peripheral selectivity in animal studies, in human clinical trials it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.

See also